会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Method for high throughput peptide/protein assay generation and assays generated therewith
    • 用于生成高通量肽/蛋白质测定法的方法和由此产生的测定法
    • US08501421B2
    • 2013-08-06
    • US12994093
    • 2009-05-20
    • Rudolf AebersoldPaola PicottiOliver RinnerJohan Malmstroem
    • Rudolf AebersoldPaola PicottiOliver RinnerJohan Malmstroem
    • G01N31/00G01N33/53
    • G01N33/6848
    • The invention relates to a method for the determination of an MRM or SRM assay for a protein of interest, a peptide of interest, or a group of proteins/peptides of interest or a whole proteome. It essentially includes the following steps: (1) a list of proteins of interest is selected and for each member at least one or a list of candidate proteotypic peptides is derived (2) this at least one peptide is synthesized/generated essentially without subsequent purification; (3) this at least one unpurified peptide is analyzed by selected reaction monitoring (SRM) preferably coupled to liquid chromatography (LC-SRM) or analogous techniques; (4) validation and/or optimisation of the corresponding assay of the at least one peptide with determination of the SRM coordinates for a peptide/protein of interest and/or of a regulator of interest is achieved. A protein sample of interest is enzymatically digested and can then be analyzed in SRM mode or time-constrained SRM mode, using elution times to trigger acquisition of the set of selected SRM traces, thus drastically increasing the throughput. The analysis allows to detect and quantify the set of peptides/proteins of interest. The method additionally relates to a tagging strategy to achieve absolute quantification of the peptides/proteins of interest at low-budget and high-throughput.
    • 本发明涉及用于确定感兴趣的蛋白质,目标肽或感兴趣的蛋白质/肽组或整个蛋白质组的MRM或SRM测定法的方法。 它基本上包括以下步骤:(1)选择目的蛋白的列表,并且对于每个成员,导出候选蛋白多肽的至少一个或一个或多个列表(2)该基因上没有随后的纯化合成/生成至少一种肽 ; (3)通过优选与液相色谱法(LC-SRM)偶联的选择性反应监测(SRM)或类似技术来分析至少一种未纯化的肽。 (4)通过确定感兴趣的肽/ /蛋白质和/或感兴趣的调节剂的SRM坐标来确定和/或优化至少一种肽的相应测定。 感兴趣的蛋白质样品被酶消化,然后可以以SRM模式或时间受限的SRM模式进行分析,使用洗脱时间来触发所选择的SRM迹线的采集,从而大大增加产量。 该分析允许检测和定量所组合的肽/蛋白质。 该方法另外涉及在低预算和高通量下实现目标肽/蛋白质的绝对定量的标记策略。
    • 3. 发明申请
    • METHOD FOR BIOMARKER AND DRUG-TARGET DISCOVERY FOR PROSTATE CANCER DIAGNOSIS AND TREATMENT AS WELL AS BIOMARKER ASSAYS DETERMINED THEREWITH
    • US20110065605A1
    • 2011-03-17
    • US12992542
    • 2009-05-12
    • Wilhelm KrekIgor CimaRudolf AebersoldRalph SchiessThomas CernySilke Gillessen
    • Wilhelm KrekIgor CimaRudolf AebersoldRalph SchiessThomas CernySilke Gillessen
    • C40B30/04G01N33/566G01N33/68C12Q1/37H01J49/26
    • G01N33/57434G01N33/57407G01N33/6848G01N2333/47G01N2333/70525G01N2333/8146
    • The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and selecting as candidate protein/peptide biomarkers those which show a mass-spectrometrically measurable quantitative differential behaviour between healthy and cancerous sample proteomes; (c) validation of the candidate protein/peptide biomarkers as identified in step (a), or as optionally verified in step (b), by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy human individuals as well as from cancerous human individuals and selecting as protein/peptide biomarkers those which show a mass-spectrometrically measurable and/or antibody-based assay detectable differential behaviour between healthy and cancerous sample proteomes; (d) application of statistical methods to uncover single or groups of protein/peptide biomarkers as validated in step (c) as signatures for the detection of patients with cancer. The invention furthermore relates to specific biomarker assays for the highly reliable diagnosis of cancer, specifically of localized or non-localized prostate cancer, using human serum, plasma or any other derivatives of blood, or blood itself.